UNITED THERAPEUTICS Corp Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
UNITED THERAPEUTICS Corp quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q2 2024.
  • UNITED THERAPEUTICS Corp Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $49.7M, a 260% increase year-over-year.
  • UNITED THERAPEUTICS Corp Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $113M, a 77.1% increase year-over-year.
  • UNITED THERAPEUTICS Corp annual Share-based Payment Arrangement, Expense for 2023 was $39.1M, a 63.4% decline from 2022.
  • UNITED THERAPEUTICS Corp annual Share-based Payment Arrangement, Expense for 2022 was $107M, a 22.9% decline from 2021.
  • UNITED THERAPEUTICS Corp annual Share-based Payment Arrangement, Expense for 2021 was $139M, a 15.4% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $113M $49.7M +$35.9M +260% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $77.1M $25.6M +$38M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $39.1M $16.6M -$48.2M -74.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $87.3M $21.1M +$23.5M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-01
Q2 2023 $63.8M $13.8M -$51.7M -78.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $116M -$12.4M +$8.7M +41.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $107M $64.8M +$20.1M +45% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $86.7M -$2.4M -$27M -110% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $114M $65.5M +$36.4M +125% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $77.3M -$21.1M -$61.2M -153% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $139M $44.7M -$49M -52.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $188M $24.6M +$37.1M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $150M $29.1M -$22.7M -43.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $173M $40.1M +$9.3M +30.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $164M $93.7M +$64.2M +218% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-22
Q3 2020 $99.6M -$12.5M -$36.4M -152% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $136M $51.8M +$89M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $47M $30.8M +$1.6M +5.48% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $45.4M $29.5M +$26.7M +954% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $18.7M $23.9M -$27.5M -53.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 $46.2M -$37.2M -$57.7M -281% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-29
Q1 2019 $104M $29.2M +$130M Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-29
Q4 2018 -$26.4M $2.8M -$116M -97.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $89.3M $51.4M +$75.4M Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-30
Q2 2018 $13.9M $20.5M +$22.4M Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-31
Q1 2018 -$8.5M -$101M -$82M -429% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 $73.5M $119M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 -$24M Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-31
Q2 2017 -$1.9M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 -$19.1M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.